ReviewTherapeutic advances in respiratory disease
What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape.
Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of different inhaler types for asthma and chronic obstructive pulmonary disease. a systematic review and meta-analysis.NPJ primary care respiratory medicine · 2026Pooled it
- TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow.International journal of chronic obstructive pulmonary diseaseTrial
- Inhaled Corticosteroid/Long-Acting βAdvances in therapy · 2026Review
- Phone-Based Teach-To-Goal Inhaler Education Program for Medicare Advantage Beneficiaries With COPD.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026Article
- Key factors for implementing inhaler regimen switches in respiratory diseases: international expert consensus generated using a modified nominal group technique (NGT).NPJ primary care respiratory medicine · 2026Article
- Outcomes and Usability of Formoterol-Budesonide Delivered Through SynchrobreatheDrugs - real world outcomes · 2025Article
- NEXThalerJournal of clinical medicine · 2025Article
- Design, optimization, and evaluation of lyophilized lipid nanoparticles for mRNA-based pulmonary mucosal vaccination.Materials today. Bio · 2025Article
- Inhalation Innovation: Optimizing COPD Care Through Clinical Pharmacist Integration in a Rehabilitation Hospital's Multidisciplinary Team - A Quality Improvement Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2025Article
- Maintenance Inhalers for Asthma and COPD in Spain.Respiratory care · 2024Observational
- Downstream Effects of Market Changes on Inhalers: Impacts on Individuals With Chronic Lung Disease.Respiratory care · 2024Review
- Real-World Use of Inhaled COPD Medications: the Good, the Bad, the Ugly.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Aerosol Plumes of Inhalers Used in COPD.Pulmonary therapy · 2024Article
- Impact of Pharmacist-Led Intervention on Adherence to Inhalers, Inhalation Technique, and Disease Control Among Asthma/COPD Patients in a Resource Limited Center: An Interventional Study.Patient preference and adherence · 2024Article
- How Patient-Centred Are Inhaler Device Choices? A Survey of Canadian Prescribers.The Canadian journal of hospital pharmacy · 2024Article
- Feedback systems in multi-dose dry powder inhalers.Postepy dermatologii i alergologii · 2023Review
- Effectiveness of an educational intervention about inhalation technique in healthcare professionals in primary care: a cluster randomized trial.Frontiers in pharmacology · 2023Article
- Exploring General Practitioners' Preferences and Experience with Respiratory Inhaler Devices.Pulmonary therapy · 2022Article
- Article
- Impact of Sex on Proper Use of Inhaler Devices in Asthma and COPD: A Systematic Review and Meta-Analysis.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhaled therapies are the cornerstone of treatment in asthma and chronic obstructive pulmonary disease, and there are a multitude of devices available. There is, however, a distinct lack of evidence-based guidance for healthcare providers on how to choose an appropriate inhaler. This review aims to summarise recent updates on topics related to inhaler choice, and to offer practical considerations for healthcare providers regarding currently marketed devices. The importance of choosing the right inhaler for the right patient is discussed, and the relative merits of dry powder inhalers, pressurised metered dose inhalers, breath-actuated pressurised metered dose inhalers, spacers and soft mist inhalers are considered. Compiling the latest studies in the devices therapy area, this review focuses on the most common types of handling errors, as well as the comparative rates of incorrect inhalation technique between devices. The impact of device-specific handling errors on inhaler performance is also discussed, and the characteristics that can impair optimal drug delivery, such as inhalation flow rate, inhalation volume and particle size, are compared between devices. The impact of patient perceptions, behaviours and problems with inhalation technique is analysed, and the need for appropriate patient education is also highlighted. The continued development of technology in inhaler design and the need to standardise study assessment, endpoints and patient populations are identified as future research needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.